Skip to search formSkip to main contentSkip to account menu

THERATOPE

Known as: THERATOPE STn-KLH vaccine 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2004
Review
2004
Cancer vaccines have demonstrated that they can stimulate antibody and cell-mediated immune responses against tumor-associated… 
Review
2003
Review
2003
The development of active specific immunotherapy depends on the identification of altered cancer cell-specific molecules or… 
Review
2003
Review
2003
Mucin-1 (MUC-1) is a high-molecular-weight glycoprotein rich in serine and threonine residues that are O-glycosylated. Expression… 
2003
2003
The success of high-dose chemotherapy followed by autologous stem-cell rescue as treatment for breast and ovarian cancer is… 
Review
2003
Review
2003
Biomira is developing a therapeutic cancer vaccine [THERATOPE®] for treatment of breast and other cancers.1 THERATOPE® consists… 
Review
2001
Review
2001
Active specific immunotherapy (ASI) is a promising approach to treating cancer. Numerous studies in the laboratory have… 
Highly Cited
2000
Highly Cited
2000
The purpose of this study was to evaluate the toxicity and potential efficacy of administering the THERATOPE® STn-KLH cancer… 
Review
2000
Review
2000
  • M. Morse
  • Current opinion in molecular therapeutics (Print)
  • 2000
  • Corpus ID: 39168794
Active specific immunotherapy, the use of 'vaccines' to stimulate therapeutic tumor antigen-specific immune responses, holds… 
Highly Cited
1996
Highly Cited
1996
THERATOPE (Biomira Inc., Edmonton, AB, Canada) STn-KLH cancer vaccine induces strong antibody titers against both the synthetic… 
Highly Cited
1996
Highly Cited
1996
Abstract Patients with metastatic breast, colorectal or ovarian cancers received active specific immunotherapy (ASI) with…